1. | Altenergy | |
2. | TradeChem | |
3. | ChemCritique | |
4. | lopopclvp1nv3poo | |
5. | corrosivedeath |
1. | Altenergy | |
2. | TradeChem | |
3. | ChemCritique | |
4. | lopopclvp1nv3poo | |
5. | corrosivedeath |
1. | Altenergy 09/12/2017 Bank of America Merrill Lynch Global Healthcare Conference |
2. | E3attendee 02/01/2018 Misses EPS estimates by $0.14. Slightly misses on revenues. |
3. | corrosivedeath 01/30/2018 Confirms the EMA's CHMP adopted a positive opinion recommending a label variation for KYPROLIS to include u… |
4. | corrosivedeath 06/28/2018 Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine |
5. | lopopclvp1nv3poo 02/13/2018 Amgen says it's looking hard for acquisitions that make sense, |
6. | memnoch4109 05/15/2018 Mizuho Securities sets PT at $200 |
7. | ChemCritique 04/03/2018 European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma |
8. | TradeChem 09/12/2017 @Altenergy Got you! One sec. TradeChem Clicking thumbs up, bookmarking, and following me are all ways of saying, "Hey, thanks!" and is much appreciated! |
9. | ChemCritique 10/25/2017 Revenue decline but tops expectations |
10. | corrosivedeath 03/26/2018 Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes |